Active Bone Morphogenetic Protein 1 (BMP1) Homo sapiens (Human) Active protein

PCOLC; PCP; TLD; mTld; Procollagen C Proteinase; Mammalian tolloid protein

Add to Cart Distributors
Overview
Properties
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
  • Traits Freeze-dried powder, Purity > 80%
  • Isoelectric Point6.4
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Active Bone Morphogenetic Protein 1 (BMP1) Packages (Simulation)
  • Active Bone Morphogenetic Protein 1 (BMP1) Packages (Simulation)
  • APA653Hu01.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

Bone Morphogenetic Protein 1 (BMP1) is a metalloprotease that plays a crucial role in extracellular matrix (ECM) remodeling and tissue development. It processes procollagens and other ECM precursors, contributing to bone formation, wound healing, and organogenesis. Unlike other BMP family members, BMP1 lacks osteoinductive activity but is essential for activating TGF-β superfamily proteins, including growth factors involved in skeletal and connective tissue regulation. BMP1 cleaves and inactivates Myostatin (MSTN), a negative regulator of muscle growth, thereby indirectly promoting muscle hypertrophy by reducing MSTN-mediated inhibition of myogenesis.Thus a functional ELISA assay was conducted to detect the interaction of recombinant human BMP1 and recombinant human MSTN. Briefly, BMP1 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to MSTN-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-BMP1 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 µL stop solution to the wells and read at 450/630nm immediately. The binding activity of recombinant human BMP1 and recombinant human MSTN was shown in Figure 1, the EC50 for this effect is 0.014 μg/mL.

Usage

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Bone morphogenetic protein 1.3 inhibition decreases scar formation and supports cardiomyocyte survival after myocardial infarctionPubmed:35013172

Recommend products